Piperine and Its Metabolite's Pharmacology in Neurodegenerative and Neurological Diseases

Piperine (PIP) is an active alkaloid of black and long peppers. An increasing amount of evidence is suggesting that PIP and its metabolite's could be a potential therapeutic to intervene different disease conditions including chronic inflammation, cardiac and hepatic diseases, neurodegenerative diseases, and cancer. In addition, the omnipresence of PIP in food and beverages made this compound an important investigational material. It has now become essential to understand PIP pharmacology and toxicology to determine its merits and demerits, especially its effect on the central nervous system (CNS). Although several earlier reports documented that PIP has poor pharmacokinetic properties, such as absorption, bioavailability, and blood-brain barrier permeability. However, its interaction with metabolic enzyme cytochrome P450 superfamily and competitive hydrophobic interaction at Monoamine oxide B (MAO-B) active site have made PIP both a xenobiotics bioenhancer and a potential MAO-B inhibitor. Moreover, recent advancements in pharmaceutical technology have overcome several of PIP's limitations, including bioavailability and blood-brain barrier permeability, even at low doses. Contrarily, the structure activity relationship (SAR) study of PIP suggesting that its several metabolites are reactive and plausibly responsible for acute toxicity or have pharmacological potentiality. Considering the importance of PIP and its metabolites as an emerging drug target, this study aims to combine the current knowledge of PIP pharmacology and biochemistry with neurodegenerative and neurological disease therapy.

Automated summary

Piperine (PIP) has shown potential therapeutic effects in various diseases, including inflammation, cardiac and hepatic diseases, neurodegenerative diseases, and cancer. Although PIP has poor pharmacokinetic properties, its interaction with metabolic enzymes and the Monoamine oxide B (MAO-B) active site make it a xenobiotics bioenhancer and a potential MAO-B inhibitor. Advancements in pharmaceutical technology have improved PIP's limitations. However, the structure activity relationship (SAR) study suggests that some of PIP's metabolites may be toxic or have pharmacological potential.